Nine months that moved dermatology.
On 22 October, Galderma reported its first nine months of 2026 and raised its full-year guidance for the second time this year. It is the kind of story a room remembers, if the room can see it.

Robust demand for our differentiated, premium portfolio continues to drive growth.Flemming Ørnskov, M.D., MPH · CEO · Q3 2026 trading update
































